AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23047470
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ciprofloxacin 500 mg
Trial: 23047470
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of ciprofloxacin 500 mg
Trial: 20547163
Drug: Propranolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (up to 320 mg/day)
Trial: 17340594
Drug: Androgen suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression therapy (AST) and radiation therapy (RT) with 70 Gy and 6 months of AST
Trial: 15827107
Drug: GH (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.5 mg/d)
Trial: 15827107
Drug: GH (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.5 mg/d) and Testosterone (250 mg) combined
Trial: 9865428
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (1.01 mg/kg/day)
Trial: 9865428
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (2.01 mg/kg/day)
Trial: 9865428
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0.16 mg/kg/day)
Trial: 7885123
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily)
Trial: 2195936
Drug: Once-daily (OD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (OD) theophylline therapy administered in the evening at 8:00 P.M.
Trial: 2195936
Drug: Conventional twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional twice-daily (TD) theophylline therapy administered at 8:00 A.M. and 8:00 P.M.
Trial: 484815
Drug: Caudal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal analgesia (1.5 mg/kg bupivacaine)
Trial: 25887977
Drug: Repeated treatment
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated treatment with praziquantel and albendazole four times a year
Trial: 25887977
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose treatment with praziquantel and albendazole once a year
Trial: 17724558
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy twice a week for 4 weeks followed by stretching exercises
Trial: 17724558
Drug: Stretching 5
RxNorm normalized name: BANDAGE,STRETCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching 5 times a week for 4 weeks followed by manual therapy
Trial: 16202254
Drug: Sibutramine tablet
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine tablet (10-20 mg/day for 24 weeks)
Trial: 16202254
Drug: Sibutramine capsule
RxNorm normalized name: sibutramine Oral Capsule
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sibutramine capsule (10-20 mg/day for 24 weeks)
Trial: 9213594
Drug: Acute allograft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute allograft rejection treatment
Trial: 2012051
Drug: Ranitidine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administration
Trial: 2012051
Drug: Ranitidine non-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine non-administration (Control)
Trial: 20183664
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and FLX
Trial: 20183664
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (CBT, FLX, Combination, Placebo)
Trial: 15182114
Drug: Telmisartan therapy
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan therapy (40-80 mg once daily)
Trial: 12455252
Drug: Family medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family medicine preceptor
Trial: 12455252
Drug: General internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General internal medicine preceptor
Trial: 7653792
Drug: Enoximone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1.0 mg/kg)
Trial: 7653792
Drug: R80122 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R80122 (0.3 mg/kg)
Trial: 2702910
Drug: Hypoglycemia (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (50 mg/dl)
Trial: 2702910
Drug: Normoglycemia (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemia (100 mg/dl)
Trial: 2702910
Drug: Hyperglycemia (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (300 mg/dl)
Trial: 362207
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (400 to 800 micrograms per day in divided doses)
Trial: 362207
Drug: Alternate-day prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternate-day prednisone (20 to 40 mg on alternate mornings)
Trial: 362207
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate and alternate-day prednisone (used together)
Trial: 362207
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (7 children requiring only non-corticosteroid medication)
Trial: 21667021
Drug: atRA treatment
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atRA treatment
Trial: 17130503
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 or 300 mg once daily)
Trial: 7855186
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 5 weeks after a 1-week wash-out and 1-week placebo period.
Trial: 25955823
Drug: Basic body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic body awareness therapy (BAT)
Trial: 23521461
Drug: Intraarticular injection
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injection of contrast agent mixed with 2% mepivacaine
Trial: 23521461
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received contrast agent only
Trial: 20876826
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about the Drug Burden Index (DBI) provided to general practitioners (GPs) via a letter and phone call, prompting cessation or dose reduction of anticholinergic and sedative medications.
Trial: 12113193
Drug: Radiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation treatment for ductal carcinoma in situ (DCIS)
Trial: 7993148
Drug: Aspirin (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (at least 95% adherence)
Trial: 7993148
Drug: Aspirin (taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (taking < 50% of study tablets)
Trial: 3180636
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide gel, 8 gm t.i.d.
Trial: 19270030
Drug: Parent-Scored PSC
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Scored PSC administration
Trial: 19270030
Drug: Staff-Scored PSC
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staff-Scored PSC administration
Trial: 17097958
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment (group 1)
Trial: 17097958
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin treatment (group 0)
Trial: 15271745
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (SSB) with 10 mL of 0.25% bupivacaine
Trial: 15271745
Drug: Intraarticular local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular local anesthetic (IA) with 20 mL of 0.25% bupivacaine
Trial: 15271745
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block (ISB) with 20 mL of 0.25% bupivacaine
Trial: 11720825
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy (neoadjuvant chemotherapy, Patey mastectomy, postoperative radiotherapy and adjuvant hormone therapy)
Trial: 9071898
Drug: Initial hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial hormone therapy
Trial: 11720825
Drug: Both therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapy groups
Trial: 7895951
Drug: Hyperglycaemic clamping
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperglycaemic clamping (plasma glucose approximately 15 mmol/l) with somatostatin suppression of insulin secretion
Trial: 7895951
Drug: Euglycaemic clamping
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Euglycaemic clamping (plasma glucose approximately 5 mmol/l) with somatostatin infusion
Trial: 28603901
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (50 mg topical gel)
Trial: 25078052
Drug: Outpatient misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Trial: 25078052
Drug: Inpatient misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inpatient misoprostol administration (800 mcg intra-vaginally, eight hourly, maximum of three doses)
Trial: 25078052
Drug: Outpatient misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Outpatient misoprostol administration
Trial: 25078052
Drug: Inpatient misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inpatient misoprostol administration
Trial: 25078052
Drug: Both outpatient
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both outpatient and inpatient misoprostol administration
Trial: 21861719
Drug: Cinnamon 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon 1,200 mg/day
Trial: 19332203
Drug: Triple-antiplatelet therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antiplatelet therapy with cilostazol, aspirin, and clopidogrel
Trial: 19332203
Drug: Dual-antiplatelet treatment
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet treatment with aspirin and clopidogrel
Trial: 15367413
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m² followed by epirubicin 80 mg/m² (group A)
Trial: 15367413
Drug: Paclitaxel followed
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel followed by carboplatin at an AUC of 6 mg x min/ml (group B)
Trial: 9195203
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous dexamethasone (1 mg/m2)
Trial: 9195203
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral dexamethasone (2 mg)
Trial: 9195203
Drug: GH-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-releasing hormone
Trial: 3557731
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg labetalol daily for eight weeks
Trial: 3557731
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg labetalol daily for eight weeks
Trial: 29753994
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie restriction diet (22% daily reduction in energy needs)
Trial: 29753994
Drug: Both calorie
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both calorie restriction diets (daily and intermittent)
Trial: 27769310
Drug: CueS wristband
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CueS wristband providing 'live' feedback towards pre-set movement goals during a 4-week upper limb therapy programme.
Trial: 27769310
Drug: Sham CueS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham CueS wristband that monitors upper limb activity but provides no feedback during a 4-week upper limb therapy programme.
Trial: 25539929
Drug: B-type natriuretic
RxNorm normalized name: B-type natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-type natriuretic peptide (BNP) 3.0 pmol·kg(‐1)·min(‐1) during a continuous infusion lasting for 4 h
Trial: 23033237
Drug: Open-loop therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-loop therapy
Trial: 17341661
Drug: Ambulatory postremission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory postremission strategy (6 consolidation cycles administered monthly in outpatients)
Trial: 15625656
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU/day) and pioglitazone (30 mg/day)
Trial: 11171891
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus air blanket therapy (n = 113)
Trial: 11171891
Drug: Acetaminophen alone
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen alone (n = 107)
Trial: 7851271
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion to inhibit tubular reabsorption (TR) of transferrin
Trial: 28671553
Drug: High HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High HBV viral load (>6 log IU/ml) patients in LVD group
Trial: 28671553
Drug: High HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High HBV viral load (>6 log IU/ml) patients in ETV group
Trial: 22252354
Drug: GAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAA supplementation at 0.6 g/kg
Trial: 22252354
Drug: GAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAA supplementation at 1.2 g/kg
Trial: 22252354
Drug: 1.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/kg GAA
Trial: 8095137
Drug: Exposure in
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure in vivo followed by cognitive therapy
Trial: 8095137
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy followed by exposure in vivo
Trial: 8768511
Drug: Cognitive‐behavioral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral treatment integrating both strategies from the start
Trial: 8768511
Drug: Cognitive-exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-exposure treatment
Trial: 6981695
Drug: Inhaled cephaloridine
RxNorm normalized name: cephaloridine
DrugBank: Cefaloridine (DB09008)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cephaloridine
Trial: 6981695
Drug: No inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhaled antibiotic (Control)
Trial: 25943670
Drug: Internal cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal cooling (ICE, 7.5 g/kg ice slurry ingestion)
Trial: 19363967
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg, PO single dose)
Trial: 19363967
Drug: Placebo (tinted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tinted oil in clear capsule)
Trial: 9862086
Drug: Caffeine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.2 mg/kg, similar to a serving of ground coffee)
Trial: 9862086
Drug: Caffeine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.2 mg/kg, 86 mg, 172 mg, 258 mg total across three doses)
Trial: 7604149
Drug: IV yohimbine
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV yohimbine (0.4 mg/kg)
Trial: 7405249
Drug: Dimeditiapramine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimeditiapramine (1 mg/kg body weight, single intravenous dose)
Trial: 28958851
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg, subcutaneous, escalated by 0.6 mg/day for 5 weeks, continued until week 16)
Trial: 28958851
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg, subcutaneous)
Trial: 23785020
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (1st week 0.01 mg/day/kg, 2nd week 0.02 mg/day/kg, 3rd week 0.03 mg/day/kg)
Trial: 23785020
Drug: GH receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH receptor antagonist (Pegvisomant) treatment (1st week 10 mg/day, last 2 weeks 15 mg/day)
Trial: 14666956
Drug: Structured care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured care with atorvastatin (10-80 mg/day, mean 23.7 mg/day)
Trial: 14666956
Drug: Structured care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured care with atorvastatin
Trial: 8838966
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin 1 g every 8 hours for 7 days
Trial: 1283893
Drug: Finasteride therapy
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finasteride therapy for one week
Trial: 31138273
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving oral health care as usual
Trial: 29985459
Drug: Nurse-led repeated
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led repeated prescription (NRP)
Trial: 1637611
Drug: i.v. tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. tenoxicam 20 mg
Trial: 9113635
Drug: High-AA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-AA diet (1.5 g/d)
Trial: 8368552
Drug: Dezocine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine (5 mg)
Trial: 3752420
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy with birch pollen extract (20 X 10(6) BU monthly, daily for seven consecutive days every month or once weekly)
Trial: 3752420
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy with birch pollen extract (more than 2 X 10(5) BU monthly)
Trial: 3752420
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy with birch pollen extract
Trial: 31394910
Drug: Yoga (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga (twice a week for 8 weeks)
Trial: 24718821
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of radiotherapy (>30 gy to <60 gy)
Trial: 14981214
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of methylphenidate (0.5 mg/kg)
Trial: 14981214
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of methylphenidate (0.5 mg/kg)